Acrivon (ACRV) director receives 9,366 restricted stock units in equity grant

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. director Ivana Magovcevic-Liebisch received an equity award in the form of 9,366 restricted stock units of common stock. The award was granted at no cash cost to her and represents a compensation-related acquisition rather than an open-market purchase.

Each restricted stock unit gives her the right to receive one share of Acrivon common stock, but the units will vest in full only on May 18, 2027, provided she continues to serve the company through that date. Following this grant, her reported direct holding from this award is 9,366 shares, highlighting a single, time-based vesting grant rather than ongoing trading activity.

Insights

Equity compensation analyst

Director received time-based RSU grant, a routine equity compensation award.

Director Ivana Magovcevic-Liebisch was granted 9,366 restricted stock units of Acrivon Therapeutics, Inc. common stock. The grant is recorded at a price of $0.0000 per share, indicating a compensation award rather than an open-market transaction, and uses code A for grant/acquisition.

The RSUs vest in full on May 18, 2027, conditioned on continuous service, so economic value depends on both future share price and her ongoing role. There are no derivative exercises or sales reported, and post-transaction holdings shown are entirely from this grant, suggesting a standard board compensation grant rather than a signal-driven trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Magovcevic-Liebisch Ivana

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	9,366	$0.00	--

Holdings After Transaction: Common Stock — 9,366 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 9,366 units Grant price: $0.0000 per share Shares after transaction: 9,366 shares +2 more

5 metrics

RSUs granted 9,366 units Restricted stock units of common stock granted May 18, 2026

Grant price $0.0000 per share Reported transaction price per share for RSU grant

Shares after transaction 9,366 shares Total shares/units reported following the grant

Vesting date May 18, 2027 RSUs vest in full on this date, subject to service

Transaction code A Grant, award, or other acquisition of common stock

Key Terms

restricted stock units, RSUs, contingent right, continuous service, +1 more

5 terms

restricted stock units financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

continuous service financial

"These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service"

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Magovcevic-Liebisch Ivana

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2026		A(1)		9,366	A	$0	9,366	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Acrivon Therapeutics (ACRV) director Ivana Magovcevic-Liebisch report in this Form 4?

She reported receiving a grant of 9,366 restricted stock units of Acrivon Therapeutics common stock. The award is a compensation-related acquisition at no cash cost, rather than an open-market purchase or sale of existing shares.

How many ACRV shares are covered by the new equity award?

The award covers 9,366 restricted stock units, each representing one share of Acrivon Therapeutics common stock. After the grant, her Form 4 shows 9,366 shares following the transaction, reflecting the full size of this new equity grant.

When do Ivana Magovcevic-Liebisch’s ACRV restricted stock units vest?

The restricted stock units vest in full on May 18, 2027. Vesting is contingent on her continuous service with Acrivon Therapeutics through that date, meaning the shares are earned over time rather than immediately available.

Is this ACRV Form 4 transaction a market purchase or sale of shares?

No, the Form 4 shows a compensation grant coded as an acquisition (A), not an open-market trade. The 9,366 units were awarded at a reported price of $0.0000 per share as part of her director compensation package.

What conditions apply to the ACRV restricted stock units granted to the director?

The RSUs are subject to a continuous service requirement through May 18, 2027. Each unit converts into one share of common stock only if she remains in service until the vesting date, aligning compensation with ongoing board participation.

Does this ACRV Form 4 show any option exercises or derivative transactions?

No, the filing lists no derivative securities or option exercises. It reports only a single non-derivative transaction: the grant of 9,366 restricted stock units of common stock as an equity compensation award to the director.